As of June 21, 2025, Evgen Pharma PLC has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $0.54, this represents a potential upside of -6264.4%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -6485.7% |
| Potential Upside (10-year) | -6264.4% |
| Discount Rate (WACC) | 5.6% - 7.3% |
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 03-2023 | 0 | - |
| 03-2024 | 0 | -10% |
| 03-2025 | 0 | 2% |
| 03-2026 | 0 | 2% |
| 03-2027 | 0 | 2% |
| 03-2028 | 0 | 2% |
| 03-2029 | 0 | 4% |
| 03-2030 | 0 | 4% |
| 03-2031 | 0 | 2% |
| 03-2032 | 0 | 2% |
| 03-2033 | 1 | 3% |
Net profit margin is expected to improve from -915% in 03-2023 to -481% by 03-2033, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 03-2023 | (4) | -915% |
| 03-2024 | (4) | -381% |
| 03-2025 | (4) | -389% |
| 03-2026 | (4) | -396% |
| 03-2027 | (4) | -404% |
| 03-2028 | (4) | -412% |
| 03-2029 | (4) | -431% |
| 03-2030 | (4) | -448% |
| 03-2031 | (5) | -457% |
| 03-2032 | (5) | -469% |
| 03-2033 | (5) | -481% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 1% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 03-2024 | 0 |
| 03-2025 | 0 |
| 03-2026 | 0 |
| 03-2027 | 0 |
| 03-2028 | 0 |
| 03-2029 | 0 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 0 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 6M/2024 | (2) | (0) | 0 | 0 | (2) |
| 2025 | (5) | (1) | 0 | 0 | (4) |
| 2026 | (5) | (1) | 0 | 0 | (4) |
| 2027 | (5) | (1) | 0 | 0 | (4) |
| 2028 | (5) | (1) | 0 | 0 | (4) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -6485.7% |
| 10-Year DCF (Growth) | 0.00 | -6264.4% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Evgen Pharma PLC (EVG.L) a buy or a sell? Evgen Pharma PLC is definitely a sell. Based on our DCF analysis, Evgen Pharma PLC (EVG.L) appears to be overvalued with upside potential of -6264.4%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $0.54.